everyone thanks for our call. today Thanks, third for and joining Good Raf. morning, quarter us
As had financial performance. excellent outstanding We quarter. release, delivered we another you press our saw in
Our incredibly broad-based us is once to well core performing business and year. again is this demonstrating our the strength and raise full allowing for guidance
execution, performance I during on the to and and proud year-to-date reflect dynamic continuing times gains. very a market am our drive great on basis, effectively quarter As of our I navigating team’s share
by about PPI our strategy I Business later. will our and Our ongoing growth proven is and driven System talk success that more
let recap So financials. me the QX
the in $XX.XX revenue billion. Our was quarter
Our income we $X.XX adjusted delivered of performance, strong and per $X.XX another adjusted share. was billion EPS operating quarter achieving
performance by Turning continuation had strong conditions team, our driven saw resulting global second in to market as quarter, we of in QX. our was outstanding share a and good This gain. end the markets, we in from meaningful execution
customers, highlighted businesses. Let growth these bioproduction give me pharma delivered saw across with by and you with we some our mid-teens. outstanding performance excellent pharma the businesses services growth We color. Starting in additional biotech, the now serving and
in proposition Our biosciences in is our and further resonating in status. strong and government, academic partner growth differentiated our microscopy customers value mid our we elevate customer and trusted helping the to In single-digits electron saw quarter. businesses. with grew We the
we for the grew quarter. applied, the and industrial in to Turning high-teens
led the lower businesses. by transplant and our And good In across serving diagnostics all microbiology businesses strength was approximately core this these end prior expected, our we finally, of business XX% healthcare, instrument than as broad-based analytical market, diagnostics quarter. year our revenue in delivered have and We customers. growth
fueling made over growth turn another and of investments years are quarter enabled growth excellent returns. we has past to performance. So The strong our now generating which have let few me strategy, the
delivering As our value leveraging and of scale markets, our in the consists and proposition developing a high-growth to products, emerging three pillars: new innovative unique a reminder, high-impact customers. strategy our
me with Let start innovation.
Our of world’s QX further just position give We and challenges. innovation some to like you I’d the on our few our strengthened address customers greatest high-impact focus to in enables highlights. a
provide instrument proteins introduced launching treatments implicated an the sample operate Conference. microscope quarter, how cells, more and for Scientific Thermo Arctis and we cryoelectron diseases research into molecules Thermo Ion we International Orbitrap instrument clinically Scientific within our Focused During that the industry-leading automated advanced enabling more help mass sensitive the Cryo-Plasma microscopy, Mass electron Orbitrap and infectious and spectrometer metabolomics neurogenerative proteomics for analysis relevant Beam, in into Spectrometry other In biomarkers insights portfolio, cancer. in Tribrid Ascend the This will during disorders. faster, insights This streamlines tomography. breakthroughs provides
and next-generation CE-IVD with doctors patients. run approved system, patients are to recently sequencing Reporter understand, detects Dx which offering continue These We advance trials. our in software, clinical tumor cancer on medicine portfolio allowing therapies precision of sequencing medicine to better closer precision to and samples diagnose match launched also NGS bringing Oncomine use our power cancer. care and to the a certification to genomic our Test and to designed clinical treat next-gen Oncomine Ion products improve help the Dx Express recently helps technology abnormalities customers and received by Torrent Genexus We
them are we online growth. demand continue status investments true we customers, trusted made our driving meet past is and value Another rational It’s enables them is on have particularly that our our to capacity build for more delivering our where services. the as years in for a with about new over and own and for we our and achieve our to our pharma bring proposition. the growth across incredible biotech key of company customer our customers and do makes goals pillar productivity capabilities strategy way leveraging innovation capabilities couple and of their business it This to to we strong have accelerated for all The the that products partner us.
couple Let examples. me of share a
opened Chelmsford, we manufacture technologies production beads facility in site will quarter, resin the of a used This purification the in Massachusetts. During biologics.
by purification facility meet growing will increasing have which our we know, their can valued new highly business, is rapidly demand. we ensure This you a customers. As
We capabilities gene our facility viral Plainville, we the network, pharma the vector utilize and medicines technologies global I our and capabilities attendance and biotech therapy and adding bringing which best our new showcase ways it had of how from in in joined services they can to single-use in facility to a this support to event. opening also pharma and and their which our instruments, the Massachusetts. significant various our market. uniqueness strengthen team our manufacturing customers can We continue were also able showcases was The customers to demonstrates utilizes bioprocessing industry-leading programs. cell analytical and terrific of
are unique further examples that proposition. just customer couple value we strengthen these trusted a demonstrate are status how and build our So, continuing of to partner our
capitalizing are this, customers includes PPD, biotech that our I pharma in business. Our my on also remarks. clinical research cover which later will
an capital the of briefly thought XXXX. to reflect our I’d on turning growth I impact on deployment, Before update in strategy
value looks invested taken and expand new we their continuing product to our have that proposition the our performance. As have our industry fantastic. with you continue it pipeline, over know, us launches have growth us. capabilities been position to The the meaningfully allowed are actions have have us the leading truly and long-term last to organic outstanding relationship meaningfully in unique year strengthened accelerate years The and this X customers customer our we
us All of is core leading enabling this industry growth. to deliver
Let you deployment. me capital give on a brief update
PPD creating combination combination is disciplined customer successfully execute of capital deployment a in revenue incredibly our continue performing our smooth a a a is quarter. is of to capital deployment is excellent The performance. is delivering and returning business which acquisition high-teens example great capital We The of how business of strategy The strategy, core the integration driving shareholder great M&A and value. to financial growth well, strategic and our shareholders.
In customers even our their are synergies an by into to meaningful support the addition, clinical revenue and is future. for capabilities brighter we needs have translating that trial excited
well enabling model. of acquisition of us All ahead drive returns deal the the on this long-term is that and short are to
quality, me way essential is PPI to This of spend strength everyday. on culture. better of goal element dynamic Business of us The moment company the a overall. improve our Let which in Business an company customer our PPI a we see times, find PPI In productivity System, helps the is experience, System. our continually our really
efficiency As also enhances with ability creation applied our and response find you today, increase was the our helps incredible acquisitions. supply inflation. to to to our know, applied it impact unlock allow offset lead in the value teams And ways to It better to challenges, to chain solve pandemic. us it’s the
whatever through PPI our benefit position Our successfully our uniquely experienced navigate the to way. and conditions along management of the team, with System, come our company Business scale macroeconomic
power our was teams, great So quarter, System. our our growth thanks fantastic and to by the of strength another the PPI of proven Business overall, it execution strategy
to on Turning social and our governance our progress priorities. environmental,
have diversity also in During that impact, reduce to great North increasing significantly and we America reduction positive the to universities, our purchase with of another quarter social electricity electricity from strategy. and announcing on pleased our graduates our half and strong commitment commitment our carbon black we progress our inclusion advance equal emissions am needs. hire to our historically ESG power to the achieved XXX very supporting XXXX ambitious colleges to priorities. Enel progressing will wind I goal our our quarter, to make so continued an U.S. agreement This footprint, renewable agreement
through review Now, and then you take at I’d our the Steve high level to will details. guidance like a updated XXXX
We are our full raising guidance. year
additional million we revenue to share. adjusted by speed growth $XXX guidance our core strength These increasing exchange raising to XX% offsetting than higher foreign modest EPS of XXXX our over are would operating our guidance enable to scale We reported And XXXX. $XX.X increased of which per our and in impact success. how $XX.XX business by we are The revenue are $X.XX billion, headwinds at the primarily the well testing. COVID-XX are customer a outlook with and more result reflects demonstrate
decision help the of our reflects guidance addition, the impact In colleagues with to our inflation. temporary
payment making one-time week’s to of approximately a salary one be will non-executive colleagues. additional We
to Business our strategy impact benefits So key execution, and results in the growth PPI outstanding of our positive proven quarter, team’s year-to-date the excellent summarize our the our third in and System. of takeaways reflect our QX
to be markets very Our strong. well performing continue business and is
market gaining are share. We
We capabilities are investments of benefits enhanced accelerated our and in new products innovative capacity. seeing the and
results in. are valuing the to In benefits Business uniquely us scale offering. experienced expanded the our position and business has addition, are continue to of dynamic research customers our we times of PPI the And living management team, delivered System our clinical navigate our excellent benefit and our
CFO, our has bright will solidify to further that, now this and us Stephen XXXX again the Stephen? incredibly of for our Williamson. I our outlook With enabled call All hand to raise future. over
